Teresa Ruthmeier

Dr. Teresa Ruthmeier

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2023 in Journal of Lipid Research
Verified
Journal Article
Open access
CDChristian Doppler
Christian Doppler
Barbara MessnerBarbara Messner
Barbara Messner
TRTeresa Ruthmeier
Teresa Ruthmeier
BSBruno Schachner
Bruno Schachner
MRMarlene Rezk-Füreder
Marlene Rezk-Füreder
DBDavid Bernhard
David Bernhard
Pathogenic mechanisms in degenerative thoracic aortic aneurysms (TAA) are still unclear. There is an ongoing debate about whether TAAs are caused by uniform or distinct processes, which would obviously have a major impact on future treatment strategies. Clearly, the ultimate outcome of TAA subgroups associated with a tricuspid aortic valve (TAV) or a bicuspid aortic valve (BAV) is the same, namely a TAA. Based on results from our own and others' studies, we decided to compare the different TAAs (TAV and BAV) and controls using a broad array of analyses, i.e., metabolomic analyses, gene expression profiling, protein expression analyses, histological characterization, and matrix-assisted laser desorption ionization imaging. Central findings of the present study are the presence of noncanonical atherosclerosis, pathological accumulation of macrophages, and disturbances of lipid metabolism in the aortic media. Moreover, we have also found that lipid metabolism is impaired systemically. Importantly, all of the above-described phenotypes are characteristic for TAV-TAA only, and not for BAV-TAA. In summary, our results suggest different modes of pathogenesis in TAV- and BAV-associated aneurysms. Intimal atherosclerotic changes play a more central role in TAV-TAA formation than previously thought, particularly as the observed alterations do not follow classical patterns. Atherosclerotic alterations are not limited to the intima but also affect and alter the TAV-TAA media. Further studies are needed to i) clarify patho-relevant intima-media interconnections, ii) define the origin of the systemic alteration of lipid metabolism, and iii) to define valid biomarkers for early diagnosis, disease progression, and successful treatments in TAV-TAAs.

11 January 2024 in Food Chemistry
Verified
Journal Article
Open access
CGClara Ganhör
Clara Ganhör
MRMarlene Rezk-Füreder
Marlene Rezk-Füreder
CDChristian Doppler
Christian Doppler
TRTeresa Ruthmeier
Teresa Ruthmeier
Christian WechselbergerChristian Wechselberger
Christian Wechselberger
DBDavid Bernhard
David Bernhard
Aluminum is added to many food colors to change their solubility. This study compares the aluminum-containing food color carmine with its aluminum-free version carminic acid (both E 120), hypothesizing that the addition of aluminum does not only change the color's solubility, but also its effects on human cells. We could show that carmine, but not carminic acid, is taken up by gastrointestinal Caco-2 and umbilical vein endothelial cells (HUVEC). Clear differences between gene expression profiles of Caco-2 cells exposed to carmine, carminic acid or control were shown. KEGG analysis revealed that carmine-specific genes suppress oxidative phosphorylation, and showed that this suppression is associated with neurodegenerative diseases such as Alzheimer and Parkinson disease. Furthermore, carmine, but not carminic acid, increased proliferation of Caco-2 cells. Our findings show that a food color containing aluminum induces different cellular effects compared to its aluminum-free form, which is currently not considered in EU legislation.

11 April 2025 in IEEE Transactions on Biomedical Engineering
Verified
Journal Article
Closed access
XHXiangyu He
Xiangyu He
KNKrishnaraj Narayanaswamy
Krishnaraj Narayanaswamy
MFMichael B. Fischer
Michael B. Fischer
LSLeonie Schmitt
Leonie Schmitt
TRTeresa Ruthmeier
Teresa Ruthmeier
Marcus GraneggerMarcus Granegger
Marcus Granegger
Objective: Operating conditions significantly influence hemolysis generation in rotodynamic blood pumps (RBPs). Previous experiments conducted under constant operating conditions have demonstrated that lower flow rates are associated with a higher normalized index of hemolysis (NIH). However, in clinical scenarios, the pump flow rate fluctuates in response to the residual cardiac function. This study aims to investigate the effects of various pulsatile operating conditions on hemolysis generation and von Willebrand Factor (vWF) degradation of RBP. Methods: To investigate these conditions, pulsatile flow experiments were conducted for 12 hours using HeartMate 3 (HM3, Abbott Inc, USA) in a hybrid mock circulatory loop with citrated human blood from hemochromatosis patients. Three operating conditions (high, low, and no residual cardiac function) were examined under two pump speed settings: normal (5400 rpm, 4.3 L/min) and low (4800 rpm, 2.5 L/min). Hemolysis was assessed by measuring delta free hemoglobin every 30 minutes (dfHb30 min) and calculating NIH. High molecular weight (HMW) vWF multimer degradation was assessed using immunoblotting. Results: There was no significant difference in dfHb30 min (p>0.388), NIH (p > 0.382), and HMW vWF multimers degradation (p > 0.364) between the three operating conditions, but differences in these parameters were observed between the normal and low speed settings. Meanwhile, a consistent trend in the hemolysis outcomes was observed with slightly elevated hemolysis in no and high pulsatility conditions of both speed settings. Conclusion: Hemocompatibility of the HM3 is not significantly affected by periodic high/low flow or backflows through the pump in in-vitro evaluation but rather by the pump operating condition: flow rate and pump speed.

Verified
Journal Article
Open access
PDF file
FWFranziska Wittmann
Franziska Wittmann
CNClemens Nebert
Clemens Nebert
TRTeresa Ruthmeier
Teresa Ruthmeier
Daniel ZimpferDaniel Zimpfer
Daniel Zimpfer
Barbara MessnerBarbara Messner
Barbara Messner
The detrimental effect of cigarette smoking has become undeniable, based on decades of research. Twenty years ago, the electronic cigarette was introduced to the market and has since then been presented as the alleged healthy alternative. Clever marketing by the industry has led to a global rise in the number of users, especially adolescents and young adults. Clinicians and scholars have praised the electronic cigarette as a tool for tobacco smoke cessation, hoping for a reduction in burden on healthcare systems. Yet accumulating evidence suggests otherwise. Over the years, several in vitro and in vivo studies in animal models and humans have shown electronic cigarettes to be associated with pulmonary, cancerous and cardiovascular diseases. This review revisits the so-far available clinical evidence concerning cardiovascular diseases and discusses research gaps that still need to be addressed, specifically focusing on patients undergoing cardiac surgery.